Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL3628 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL18593671 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL3629 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14107274 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL17813675 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL153952 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL19884331 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22450052 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22022258 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL15745871 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2376 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12370175-B2 | Glucocorticoid receptor modulators to treat pancreatic cancer | CORCEPT THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | claimed |
| US-12257251-B2 | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation | INXMED (NANJING) CO., LTD. (CN) | 2025-03-25 | — | — | US | claimed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| US-20230364088-A1 | USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION | INXMED (BEIJING) CO., LTD. (CN) | 2023-11-16 | — | — | US | claimed |
| US-20230285361-A1 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER | CORCEPT THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | US | claimed |
| US-20230145356-A1 | USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION | INXMED (NANJING) CO., LTD. (CN) | 2023-05-11 | — | — | US | claimed |
| EP-4062914-A1 | USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION | Inxmed (Nanjing) Co., Ltd. (CN) | 2022-09-28 | — | — | EP | claimed |
| CN-111411077-B | Application of small molecular substance in preparation of reagent for maintaining tendon stem cell phenotype in vitro | 浙江大学 | 2022-02-25 | — | — | CN | claimed |
| CN-111411077-A | Application of small molecular substance in preparation of reagent for maintaining tendon stem cell phenotype in vitro | 浙江大学 | 2020-07-14 | — | — | CN | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| WO-2013067543-A1 | METHODS AND COMPOSITIONS FOR ADMINISTERING A SPECIFIC WAVELENGTH PHOTOTHERAPY | FOLLEA INTERNATIONAL LTD. (CN) | 2013-05-10 | — | — | WO | claimed |
| US-20130115180-A1 | Methods And Compositions For Administering A Specific Wavelength Phototherapy | APPLIED BIOLOGY, INC. | 2013-05-09 | — | — | US | claimed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | claimed |
| US-6353124-B1 | NONSTEROIDAL ANTIINFLAMMATORY AGENTS (ASPIRIN, INDOMETHACIN, OR IBUPROFEN) LINKED BY TRIS AMINE OR ETHANOLAMINE DERIVATIVE TO THE ACYL GROUPS OF FATTY ACIDS; IMPROVED TRANSDERMAL DELIVERY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-03-05 | — | — | US | claimed |
| US-6303621-B1 | ADMINISTERING DIIODO THYRONINE ANALOGUE HAVING NO SIGNIFICANT HORMONAL ACTIVITY AND A VINCA ALKALOID SELECTED FROM LEUROSINE, VINCALEUKOBLASTINE, VINBLASTINE, LEUROFORMINE, LEUROSIDINE, LEUROCRISTINE, VINCRISTINE, DEOXY VINBLASTINE | OCTAMER, INC. | 2001-10-16 | — | — | US | claimed |
| EP-0014053-B1 | SYNTHESIS OF VINDESINE; VINCALEUKOBLASTINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1983-12-14 | — | — | EP | claimed |
| EP-0014053-A1 | Synthesis of vindesine; vincaleukoblastine compounds | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | claimed |